ARTICLE | Clinical News
Daxas roflumilast regulatory update
May 11, 2009 7:00 AM UTC
Nycomed submitted an MAA to EMEA for Daxas roflumilast to treat chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis. Daxas is an oral phosphodiesterase-4 (PDE-4) inhibitor...